Question

In hybridoma technology
(a)B-cells are fused with myeloma cells
(b)T-cells are fused with myeloma cells
(c)B-cells are fused with T-cells
(d)none of the above

Answer 1

Hint: cells that become plasma cells to produce antibodies are fused with the tumor-forming cells called myelomas to produce a hybrid cell that is immoral and produces monoclonal antibodies.

Complete answer:
Production of monoclonal antibodies by the fusion of short-lived immune cells and myeloma cells which are immoral.
B cells are converted into plasma cells in the thymus and these plasma cells produce antibodies against foreign organisms. Myeloma cells are abnormal plasma cells in the bone marrow that form tumor cells. They are immortal. When B-cell is fused with myeloma cells it gives hybrid cells that can produce monoclonal antibodies and attain immortality.

Additional Information: 1. Hybridoma technique was discovered by J.F.Kohler and Cesar Milstein and they got the Nobel prize for this discovery.
2. They discovered a hybrid cell that has the property of a B-cell to produce immorality of myeloma cells. Due to this feature, it can produce numerous monoclonal antibodies. This is called hybridoma technology.
3. Monoclonal antibodies are identical antibodies because they are produced by one type of immune cell. They are produced by plasma cells used in the treatment of cancer cells and anti-venom
4. The hybrid cell is produced initially by immunization of a specific animal that can generate plasma cells against that antigen. myeloma cells are isolated from bone marrow and are fused with spleen results in the production of hybridoma cells. They are isolated and fused with the plasma cells resulting in the production of the hybrid cells.
So, the correct answer is ‘B-Cells are fused with myeloma cells’.

Note: Hybridoma technology is used in the identification of blood groups, detection of pregnancy, separation of a substance from a mixture, removal of tumor cells from bone marrow, treatment of malignant leukemic cells, B cell lymphomas, and graft rejections after transplantation.